How to Get Vyleesi (Bremelanotide) in Wisconsin

What Is Vyleesi and Why Was It Approved?

Bremelanotide is a melanocortin-4 receptor agonist that the FDA approved in June 2019 for HSDD in premenopausal women. It is the only on-demand, injectable treatment for this condition. The drug works by activating central nervous system pathways involved in sexual desire rather than targeting peripheral blood flow.

The approval rested on the RECONNECT phase 3 program, which enrolled 1,247 premenopausal women with HSDD across two double-blind, placebo-controlled trials. At 24 weeks, women receiving bremelanotide 1.75 mg reported a statistically significant increase in desire scores on the Female Sexual Function Index (FSFI-d) compared with placebo (mean change +0.35 vs. +0.13, P<0.001). Distress scores on the Female Sexual Distress Scale (FSDS-DAO Item 13) also dropped significantly. The FDA prescribing label notes that bremelanotide should not be used in patients with uncontrolled hypertension or known cardiovascular disease, because transient blood pressure increases of 6 to 12 mmHg systolic occur within 2 to 3 hours of injection.

Nausea is the most common adverse event, affecting about 40% of patients after the first dose. That rate drops to roughly 20% by the second month of use, according to the RECONNECT extension data. Focal hyperpigmentation of the face, gums, or breasts may also develop with repeated dosing, and the label recommends discussing this possibility before initiating therapy.

Wisconsin Prescribing Rules for Bremelanotide

Any Wisconsin-licensed prescriber with independent prescriptive authority can write a Vyleesi prescription. That includes MDs, DOs, nurse practitioners, and physician assistants.

Wisconsin Statute § 448.9865 and the state's telehealth parity law (2021 Wisconsin Act 134) allow clinicians to prescribe medications after a synchronous audio-video encounter. No prior in-person visit is required for bremelanotide. The prescriber must hold an active Wisconsin license or a license recognized under an interstate compact. If you are seeing a telehealth provider based out of state, confirm that they are registered with the Wisconsin Department of Safety and Professional Services before your appointment.

A typical telehealth visit for Vyleesi takes 15 to 25 minutes. The clinician will confirm your HSDD diagnosis using the decreased sexual desire screener (DSDS), review your cardiovascular history, and check a baseline blood pressure reading. You can take your own blood pressure at home with a validated cuff, or submit a reading from a recent primary care visit.

What Labs and Screenings Are Required?

There is no lab panel mandated by the FDA label for bremelanotide initiation. Your prescriber will focus on ruling out medical or medication-related causes of low desire before confirming an HSDD diagnosis.

Expect the clinician to review thyroid function (TSH) if not checked within the prior 12 months, since hypothyroidism can mimic HSDD. A prolactin level may be appropriate if you report galactorrhea or menstrual irregularities. The Endocrine Society's 2019 guidelines on female sexual dysfunction recommend testing free testosterone in women with low desire, though bremelanotide's mechanism does not depend on androgen levels, and low testosterone alone does not disqualify a patient from treatment.

A blood pressure reading within 30 days of the first prescription is standard practice. If systolic pressure exceeds 140 mmHg or diastolic exceeds 90 mmHg, the prescriber will typically defer bremelanotide until hypertension is controlled. The label contraindicates use in uncontrolled hypertension due to the drug's transient pressor effect.

No hepatic or renal panels are FDA-required. Bremelanotide is metabolized by hydrolysis into amino acid fragments, and the FDA pharmacokinetic review showed no clinically relevant accumulation in mild-to-moderate hepatic or renal impairment. Severe hepatic impairment (Child-Pugh C) has not been studied; prescribers may exercise caution in that population.

How to Get Vyleesi Through Telehealth in Wisconsin

Telehealth is the fastest path for most Wisconsin residents. Several national platforms and Wisconsin-based sexual health clinics offer bremelanotide consultations. Here is the standard sequence:

Step 1: Schedule a visit. Choose a telehealth platform that explicitly lists HSDD or Vyleesi in its formulary. Verify the prescriber holds a Wisconsin license.

Step 2: Complete the intake. You will fill out a medical questionnaire covering sexual health history, current medications, cardiovascular risk factors, and a validated desire screener such as the DSDS or FSFI.

Step 3: Attend the consultation. During the video visit, the clinician confirms your HSDD diagnosis, reviews your blood pressure, discusses the 40% first-dose nausea rate, and explains proper subcutaneous injection technique.

Step 4: Receive your prescription. The clinician sends an electronic prescription to your chosen pharmacy. If the pharmacy is a 503A compounder, the prescriber writes a patient-specific prescription for bremelanotide 1.75 mg/0.3 mL prefilled syringes.

Step 5: Pharmacy fulfillment. Brand-name Vyleesi ships from a specialty pharmacy. Compounded bremelanotide ships from a licensed 503A facility, typically arriving via cold-chain courier in 3 to 7 business days.

Total time from booking to receiving medication is typically 5 to 10 business days, shorter if the pharmacy has stock and prior authorization is not required.

503A Compounding Pharmacies in Wisconsin

Wisconsin licenses 503A compounding pharmacies through the Pharmacy Examining Board under Wis. Admin. Code § Phar 8. These pharmacies can compound bremelanotide from bulk pharmaceutical-grade powder when they hold a valid patient-specific prescription. They cannot compound "copies" of commercially available Vyleesi without a documented clinical difference (such as a different concentration or preservative-free formulation).

Compounded bremelanotide often costs 40% to 60% less than brand-name Vyleesi. A 4-dose supply of compounded bremelanotide typically runs $80 to $150 out of pocket, compared with $250 to $400 for brand-name Vyleesi at a specialty pharmacy. Prices vary by pharmacy and volume.

Patients in rural Wisconsin (areas like Eau Claire, Wausau, or La Crosse) may find compounding especially practical because 503A pharmacies can ship directly to a home address. Verify the pharmacy is Wisconsin-licensed and ask whether they use cold-chain packaging, since bremelanotide prefilled syringes require storage between 20°C and 25°C.

Wisconsin Medicaid and Private Insurance Coverage

Wisconsin Medicaid (BadgerCare Plus and fee-for-service) lists Vyleesi as a covered drug with prior authorization. The PA process confirms the diagnosis of HSDD in a premenopausal woman, documented failure or intolerance of non-pharmacologic approaches, and that the prescriber has reviewed cardiovascular contraindications.

Private insurers in Wisconsin handle bremelanotide inconsistently. Some commercial plans cover Vyleesi under specialty pharmacy tiers with a $50 to $150 copay. Others classify it as non-formulary, pushing the full cost to the patient. A 2023 JAMA Network Open analysis found that only 37% of commercial plans covered any FDA-approved HSDD pharmacotherapy without step therapy requirements.

For patients facing coverage denials, these options can reduce cost:

• Manufacturer savings card. Eligible commercially insured patients may reduce out-of-pocket cost to as little as $0 per fill, subject to annual caps.
• Compounded bremelanotide. As noted, compounded versions are not processed through insurance but carry a lower cash price.
• Appeal with clinical documentation. If a prior authorization is denied, the prescriber can submit a peer-to-peer review with documentation of HSDD diagnosis, FSFI scores, and the patient's treatment history. Wisconsin's external review law (Wis. Stat. § 632.835) allows patients to request an independent review of a final adverse determination.

Prior Authorization Documentation Checklist

Wisconsin Medicaid and most commercial payers require these items for Vyleesi PA:

1. Confirmed HSDD diagnosis using DSM-5 criteria (302.71 / F52.0)
2. Statement that the patient is premenopausal
3. Documentation that distress is not better explained by a mental health disorder, relationship factors, medication side effects, or another medical condition
4. Blood pressure reading within the past 30 days
5. Cardiovascular history confirming no uncontrolled hypertension
6. List of current medications (to check for interactions with naltrexone, which can blunt bremelanotide efficacy)
7. Attestation that the patient has been counseled on nausea, injection technique, and hyperpigmentation risk

Turnaround on a PA decision is typically 3 to 5 business days for Medicaid and 5 to 15 calendar days for commercial payers. Expedited review (24 to 72 hours) is available when the prescriber certifies clinical urgency.

Transferring a Vyleesi Prescription to Wisconsin

If you hold a valid Vyleesi prescription from another state, a Wisconsin pharmacist can accept a transferred prescription under Wis. Admin. Code § Phar 7.06, provided the original prescription is not a Schedule II controlled substance (bremelanotide is not scheduled). The transferring pharmacist in the originating state calls or sends a secure electronic transfer to the receiving Wisconsin pharmacy.

If you are switching prescribers rather than pharmacies, the new Wisconsin clinician will need to conduct their own evaluation before writing a new prescription. They can request medical records from your previous provider to simplify the process. This often takes one visit.

Prescriber Scope: MD vs. NP vs. PA

Wisconsin grants full prescriptive authority to nurse practitioners under 2017 Wisconsin Act 320, which removed the collaborative agreement requirement for NPs with 3,500+ clinical hours. PAs prescribe under a collaborative agreement with a supervising physician. Both NPs and PAs can legally prescribe bremelanotide.

From a practical standpoint, your choice of prescriber type does not affect the PA process or the prescription itself. The only difference: if a PA's supervising physician agreement does not cover sexual health medications, the PA may need to update that agreement before writing the prescription. Ask during scheduling to avoid delays.

Safety Monitoring After Starting Vyleesi

No mandatory post-initiation lab monitoring is required. The FDA label recommends periodic blood pressure checks, especially during the first month of use. If transient hypertension becomes symptomatic (headache, flushing, dizziness within 2 hours of injection), the prescriber may reduce use frequency or discontinue the drug.

Watch for these signs:

• Nausea lasting more than 3 hours. The RECONNECT data showed median nausea duration of 2 hours. Taking an antiemetic (ondansetron 4 mg) 30 minutes before the bremelanotide injection can reduce severity, per a post-hoc analysis published in the Journal of Sexual Medicine.
• Skin darkening. Hyperpigmentation occurred in 1% of trial participants and is more common with frequent dosing (more than 8 times per month). It may be irreversible.
• Injection site reactions. Bruising or redness at the injection site affected about 5% of RECONNECT participants and is managed with rotation of injection sites (abdomen or thigh).

The prescriber should schedule a follow-up at 8 to 12 weeks after initiation to assess efficacy using the FSFI-d and to screen for side effects. If desire scores have not improved by 8 weeks, continuing therapy is unlikely to produce benefit based on the RECONNECT responder analysis.

What to Expect: Timeline From First Click to First Dose

Here is a realistic timeline for a Wisconsin patient starting from scratch:

| Step | Timeframe | |---|---| | Book telehealth appointment | Day 1 | | Complete intake forms and provide BP reading | Day 1-2 | | Video consultation and prescription sent | Day 2-4 | | Prior authorization (if needed) | Day 4-9 | | Pharmacy fills and ships | Day 5-12 | | Medication arrives at home | Day 7-14 |

Patients using compounded bremelanotide without insurance billing often receive their medication by Day 7. Those routing through specialty pharmacy with PA can expect closer to 10 to 14 days.